59 DOCUMENTO SIPREC 2022 71. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56-65. 72. Grassi G, Seravalle G, Dell’Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS Study. J Hypertens. 2003;21:1761-9. 73. Dorrestein JA, Schrover IM, Visseren FL, et al. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo controlled cross-over trial. J Hypertens. 2013;31:393-403. 74. Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol. 2010;10:676-83. 75. Pischon T, Sharma AM. Use of beta blockers in obesity hypertension: potential role of weight gain. Obes Rev. 2001;2:275-80. 76. Kaiser T, Heise T, Nosek L, et al. Influence of nebivololo and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24:1397-403. 77. Byrd JB, Brook RD. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. J Hum Hypertens. 2014;28:3-9. 78. Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60:621-9. 79. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatmentresistant hypertension (The Symplicity HTN-2 trial): a randomized controlled trial. Lancet 2010;376:1903-9.
RkJQdWJsaXNoZXIy NDUyNTU=